Public COA audit

Tesamorelin

Audited July 29, 2026

Mostly consistent, with concerns

Several fields check out, but we found issues worth reviewing before you rely on this document.

Legitimacy
92
Confidence
93%
Panels
2/7
Purity (printed)
99.6%

Document details

Fields extracted from the certificate — not order or payment data.

Batch / lot
WL-TSM10-P00520
Identity method
FTIR (USP <197A>)
Sample date
2026-06-08
Issue date
2026-06-12

7-panel checklist

Had data + good, had data + bad, reported without pass/fail, or missing. Missing lowers thoroughness — you decide whether that panel matters; PeptIQ’s score still factors coverage.

2 of 7 present · 2 passed · 0 failed · 0 reported · 5 missing

Missing is a thoroughness gap — not automatically bad. PeptIQ’s legitimacy score still weighs panel coverage; you can down-weight panels that don’t matter for your use case.

  • Identity

    Tested · passed · core

    Compound identity confirmed (e.g. HPLC, mass spec).

    FTIR sample spectrum confirms the presence of Tesamorelin with addition of excipient(s)/fillers

  • Purity

    Tested · passed · core

    Reported purity percentage for the analyte.

    99.6%

  • Heavy metals

    Not on this COA

    Lead, arsenic, cadmium, mercury, or similar limits.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

  • Microbial

    Not on this COA

    Bioburden / microbial limits testing.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

  • Endotoxin

    Not on this COA · core

    LAL or chromogenic endotoxin assay.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

  • Sterility

    Not on this COA

    Sterility testing where applicable.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

  • Residual solvent / water

    Not on this COA

    Residual solvents or water content limits.

    No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.

How to read this

Had data · good

Panel present with a pass (or clear acceptance).

Had data · bad

Panel present with a fail — a concrete quality signal.

Had data · unclear

Value reported without an explicit pass/fail mark.

Missing

Not on this certificate. Lowers thoroughness; you decide if that panel matters for your use case. PeptIQ’s score still factors coverage.

Findings

Evidence-linked observations from this audit.

  • High HPLC purity confirmed

    99.6% purity by HPLC (USP <621>) meets specification of ≥98%. This is normal for research-grade peptides.

  • Identity confirmed by FTIR

    FTIR spectrum confirms Tesamorelin presence with excipients/fillers, consistent with formulated peptide product.

  • Batch information complete

    Lot number WL-TSM10-P00520, BT Sample ID 005000040403815, labeled potency 10 mg, actual potency 11 mg (110.4%).

  • Dates are consistent and current

    Date tested: 2026-06-08, Issue date: 2026-06-12. Both dates are reasonable and within normal turnaround time.

  • Lab information provided

    BTLabs, West Palm Beach, FL with contact information and website. Document includes QR code and report number IF-824-QSA-TR006-BTL2718-12.

  • Limited testing scope

    Document explicitly states it does not provide information on particulate matter, microbial contamination, or endotoxins. Only identity, purity, and potency testing performed.

  • Professional presentation

    Document includes FTIR spectrum, HPLC chromatogram, signatures of two scientists (Andrea Castro, AS and Verna Zheng, AS), and proper USP method references.

PeptIQ COA reports analyze document content and publicly verifiable lab signals. They are educational and not a guarantee of product quality, legality, or safety. Always consult a qualified professional before making health decisions. We never publish purchase prices, shipping details, or uploader identity.